A Phase II Trial of R115777 (NSC #702818) in Patients With Advanced Pancreas Cancer
OBJECTIVES: I. Determine the six month survival rate in patients with advanced
adenocarcinoma of the pancreas treated with R115777. II. Determine the time to treatment
failure and confirmed response in this patient population treated with this regimen. III.
Evaluate the frequency and severity of toxicities associated with this treatment regimen in
these patients.
OUTLINE: Patients receive oral R115777 twice daily on days 1-21. Treatment repeats every 28
days in the absence of disease progression or unacceptable toxicity. Patients are followed
every 6 months for 2 years and then annually thereafter.
PROJECTED ACCRUAL: A total of 21-50 patients will be accrued for this study.
Interventional
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Survival rate in patients with advanced adenocarcinoma of the pancreas treated with R115777
6 months
No
John S. MacDonald, MD
Study Chair
St. Vincent's Comprehensive Cancer Center - Manhattan
United States: Federal Government
CDR0000067846
NCT00005832
June 2000
October 2005
Name | Location |
---|---|
USC/Norris Comprehensive Cancer Center | Los Angeles, California 90033-0800 |
CCOP - Upstate Carolina | Spartanburg, South Carolina 29303 |
University of California Davis Medical Center | Sacramento, California 95817 |
CCOP - Wichita | Wichita, Kansas 67214-3882 |
CCOP - Kansas City | Kansas City, Missouri 64131 |
Veterans Affairs Outpatient Clinic - Martinez | Martinez, California 94553 |
CCOP - Central Illinois | Springfield, Illinois 62526 |
CCOP - Montana Cancer Consortium | Billings, Montana 59101 |
CCOP - Columbus | Columbus, Ohio 43206 |
CCOP - Greenville | Greenville, South Carolina 29615 |
University of Texas Medical Branch | Galveston, Texas 77555-1329 |
Veterans Affairs Medical Center - Wichita | Wichita, Kansas 67218 |
CCOP - Virginia Mason Research Center | Seattle, Washington 98101 |
CCOP - Northwest | Tacoma, Washington 98405-0986 |